Inhalable Biologics Market Report 2026

Inhalable Biologics Market Overview

• Inhalable Biologics market size has reached to $3.22 billion in 2025 • Expected to grow to $6.67 billion in 2030 at a compound annual growth rate (CAGR) of 15.6% • Growth Driver: Rise In Respiratory Disorders Fueling The Growth Of The Market Due To Growing Need For Targeted Pulmonary Therapies • Market Trend: Innovative Inhalable Insulin Solutions Enhance Diabetes Management And Patient Compliance • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Inhalable Biologics Market?

Inhalable biologics are biologic drugs administered through the respiratory tract via inhalation. This delivery method allows for targeted treatment of lung diseases or systemic therapy by directly reaching the lungs, enhancing drug effectiveness, and reducing side effects. The main types of inhalable biologics are peptides and proteins, vaccines, monoclonal antibodies, RNAi-based therapeutics, and others. Peptide and protein therapeutics are bioactive molecules designed to modulate specific cellular pathways or replace deficient proteins. It includes various dosage forms such as dry powder inhalers, metered dose inhalers, nebulizers, and others distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It finds applications in respiratory diseases, diabetes, cancer, and others.

What Is The Inhalable Biologics Market Growth Forecast?

The inhalable biologics market size is expected to see rapid growth in the next few years. It will grow to $6.67 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to growth in chronic respiratory disorders, expansion of inhalable biologics beyond respiratory indications, increasing patient preference for non-invasive therapies, advancements in formulation stability, rising investments in pulmonary drug delivery research. Major trends in the forecast period include expansion of pulmonary delivery for systemic biologics, growing use of dry powder inhalers for biologics, rising focus on targeted lung drug delivery, increasing development of inhalable monoclonal antibodies, adoption of patient-friendly non-invasive biologic therapies.

Global Inhalable Biologics Market Segmentation

1) By Type: Peptides And Proteins, Vaccines, Monoclonal Antibodies, RNAi-Based Therapeutics, Other Types 2) By Dosage Form: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers, Other Dosage Forms 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By Application: Respiratory Diseases, Diabetes, Cancer, Other Applications Subsegments: 1) By Peptides And Proteins: Insulin, Growth Hormones, Enzyme Replacement Therapies, Other Peptides And Proteins 2) By Vaccines: Influenza Vaccines, Other Respiratory Vaccines 3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies, Immunomodulatory Monoclonal Antibodies, Other Monoclonal Antibodies 4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases, Other RNAi-Based Therapeutics 5) By Other Types: Gene Therapies, Small Molecule Inhalable Drugs, Other Innovative Inhalable Biologics

What Is The Driver Of The Inhalable Biologics Market?

The increasing respiratory conditions are expected to propel the growth of the inhalable biologics market going forward. Respiratory conditions refer to diseases and disorders affecting the lungs and other parts of the respiratory system, including the airways, nasal passages, and lungs. The prevalence of respiratory conditions is due to increasing air pollution, which aggravates conditions such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer by exposing individuals to harmful particulate matter and other pollutants. Inhalable biologics are beneficial for respiratory conditions as they deliver targeted treatment directly to the lungs, reducing inflammation and improving lung function with fewer systemic side effects. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, COPD made up 3.6% of the total disease burden and 50% of the respiratory disease burden. Therefore, the increasing respiratory conditions significantly contribute to expanding the inhalable biologics industry.

Key Players In The Global Inhalable Biologics Market

Major companies operating in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann‑La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation

Global Inhalable Biologics Market Trends and Insights

Major companies operating in the inhalable biologics market are focusing on developing innovative solutions, such as inhaled insulin, to improve patient compliance and provide rapid glycemic control. Inhaled insulin is a form of insulin delivered into the bloodstream through the lungs via inhalation rather than through injection or insulin pumps. This method involves inhaling a powder or aerosolized form of insulin, which is absorbed through the lungs and quickly enters the bloodstream to help regulate blood sugar levels. For instance, in February 2025, Cipla Limited, an India-based pharmaceutical company, received regulatory approval from the Central Drugs Standard Control Organization for Afrezza, the world’s fastest inhaled insulin, offering a revolutionary, needle-free option for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin works within 12 to 15 minutes of inhalation, closely mimicking natural insulin response to meals and improving blood sugar control. The inhaled insulin offers a more comfortable alternative to multiple daily injections, particularly benefiting patients with injection anxiety and enhancing adherence to insulin therapy.

What Are Latest Mergers And Acquisitions In The Inhalable Biologics Market?

In October 2025, Merck & Co., Inc. (USA‑based provider of pharmaceuticals, vaccines, and cardio‑pulmonary therapies) acquired Verona Pharma for US$ 10 billion. With this acquisition, Merck aimed to strengthen and diversify its cardio‑pulmonary / respiratory portfolio by adding a novel inhaled therapy. Verona Pharma is a UK‑based biopharmaceutical company specializing in respiratory diseases, primarily developing Ohtuvayre (ensifentrine), a first‑in‑class inhaled dual PDE3/4 inhibitor for COPD.

Regional Insights

North America was the largest region in the inhalable biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Inhalable Biologics Market?

The inhalable biologics market consists of sales of inhaled antibodies, inhalable mRNA-based therapeutics, inhaled vaccines, inhaled enzyme replacement therapies, and inhalable gene therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Inhalable Biologics Market Report 2026?

The inhalable biologics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the inhalable biologics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.